Heeding the recommendation of an independent data monitoring committee, Calcimedica Inc. said it is discontinuing the phase II study testing calcium release-activated calcium channel inhibitor Auxora ...

CalciMedica has terminated a Phase II study on its lead asset, Auxora (zegocractin), in acute kidney injury (AKI) with ...

According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly ...

CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety concerns.

CalciMedica shares were 82% lower, at 91 cents, after the company said it was discontinuing its Phase 2 clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with ...

Immune checkpoint inhibitor (ICI) pneumonitis is a potentially life-threatening immune-related adverse event associated with ICI therapy across various malignancies. ICIs enhance antitumour immunity ...

Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora in AKI to be evaluated after data analysis LA ...

CalciMedica had been evaluating the therapy, called Auxora, in the Kourage trial of patients with stage 2 or 3 AKI with ...

CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company developing novel calcium ...

Investing.com -- CalciMedica Inc. (NASDAQ:CALC) stock plunged 80% Wednesday after the company announced it was discontinuing its Phase 2 KOURAGE clinical trial for acute kidney injury following safety ...

Infective endocarditis (IE) can be complicated by acute heart failure and bacteremia, which can account for increased mortality. The role of anticoagulation with warfarin in IE is controversial. This ...

1 Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China 2 School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China Background ...